CHISON MEDICAL(SH:688358) Sou Hu Cai Jing·2026-02-09 11:29Core Viewpoint - Xiangsheng Medical (688358) has shown a mixed financial performance with a decline in revenue and net profit for the first three quarters of 2025, while the third quarter showed a significant increase in net profit compared to the previous year [1] Financial Performance - For the first three quarters of 2025, the company's main revenue was 343 million yuan, a year-on-year decrease of 5.27% [1] - The net profit attributable to shareholders was 93.92 million yuan, down 4.56% year-on-year [1] - The net profit after deducting non-recurring gains and losses was 86.97 million yuan, a decrease of 2.69% year-on-year [1] - In Q3 2025, the single-quarter main revenue was 107 million yuan, a decline of 6.68% year-on-year [1] - The single-quarter net profit attributable to shareholders was 24.22 million yuan, an increase of 41.95% year-on-year [1] - The single-quarter net profit after deducting non-recurring gains and losses was 23.14 million yuan, an increase of 53.63% year-on-year [1] - The company's debt ratio stands at 11.24%, with investment income of 3.01 million yuan and financial expenses of -16.53 million yuan [1] - The gross profit margin is reported at 59.82% [1] Market Activity - As of February 9, 2026, the stock closed at 35.76 yuan, with a slight increase of 0.14% [1] - The turnover rate was 1.45%, with a trading volume of 16,300 hands and a transaction amount of 58.01 million yuan [1] - On February 9, the net outflow of main funds was 4.99 million yuan, accounting for 8.6% of the total transaction amount, while retail funds saw a net inflow of 1.02 million yuan, accounting for 1.75% [1] Analyst Ratings - In the last 90 days, three institutions have given buy ratings for the stock [2]